At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Jul 14, 2026 at 15:34 ET
Cytokinetics CEO Robert Blum exercised and sold 7,490 shares for ~$614K on July 13, and EVP R&D Fady Malik sold 3,500 shares for ~$303K on July 7. The CEO's sale follows a derivative exercise at $10.60, representing a large realized gain. The total cluster value of ~$917K is ~0.009% of the $10.2B market cap, trivial relative to company size. These are routine liquidity-driven sales, not a bearish signal.
- CEO Blum exercised 7,490 options at $10.60/share and immediately sold the shares at $82.02, netting ~$614K in proceeds
- EVP R&D Malik sold 3,500 shares at $86.62 for ~$303K on July 7
- Total cluster value of ~$917K represents ~0.009% of CYTK's $10.2B market cap
- Both sales are open-market transactions; no 10b5-1 plan indicated
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access